NCT06630884 Inflammatory Challenge and Fear
| NCT ID | NCT06630884 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of California, San Francisco |
| Condition | Posttraumatic Stress Disorder (PTSD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 288 participants |
| Start Date | 2025-03-28 |
| Primary Completion | 2028-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 288 participants in total. It began in 2025-03-28 with a primary completion date of 2028-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn if short-term changes in the immune system alter how we process information and experience fear. The main questions it aims to answer are: Do people who receive typhoid vaccine respond differently than those who receive a placebo saline vaccine? Do people who receive typhoid vaccine experience changes in how they think and feel? Participants will: Attend four appointments at the San Francisco VA Health Care System; Receive typhoid vaccine or placebo at one of the visits; Have their physiological responding measured while listening to sounds; Complete questionnaires and psychological tests.
Eligibility Criteria
Inclusion Criteria: All Subjects: 1. Aged 18-60 years old 2. Trauma Exposed 3. Current PTSD/No history of PTSD Exclusion Criteria: 1. Contraindications to typhoid vaccine 2. Conditions associated with inflammation 3. Pregnancy or plans to become pregnant in next three months
Contact & Investigator
Aoife O'Donovan, PhD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT06630884 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Posttraumatic Stress Disorder (PTSD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06630884 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06630884 currently recruiting?
Yes, NCT06630884 is actively recruiting participants. Contact the research team at aoife.odonovan@ucsf.edu for enrollment information.
Where is the NCT06630884 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT06630884 clinical trial?
NCT06630884 is sponsored by University of California, San Francisco. The principal investigator is Aoife O'Donovan, PhD at University of California, San Francisco. The trial plans to enroll 288 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.